- Home
- NDMO vs CRMD Comparison
NDMO vs CRMD Comparison
Compare NDMO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- CRMD
- Stock Information
- Founded
- NDMO 2019
- CRMD 2006
- Country
- NDMO United States
- CRMD United States
- Employees
- NDMO N/A
- CRMD N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- CRMD Health Care
- Exchange
- NDMO Nasdaq
- CRMD Nasdaq
- Market Cap
- NDMO 596.2M
- CRMD 738.4M
- IPO Year
- NDMO N/A
- CRMD 2010
- Fundamental
- Price
- NDMO $10.38
- CRMD $12.49
- Analyst Decision
- NDMO
- CRMD Strong Buy
- Analyst Count
- NDMO 0
- CRMD 6
- Target Price
- NDMO N/A
- CRMD $15.67
- AVG Volume (30 Days)
- NDMO 218.6K
- CRMD 1.3M
- Earning Date
- NDMO 01-01-0001
- CRMD 03-11-2025
- Dividend Yield
- NDMO 6.75%
- CRMD N/A
- EPS Growth
- NDMO N/A
- CRMD N/A
- EPS
- NDMO N/A
- CRMD N/A
- Revenue
- NDMO N/A
- CRMD $12,262,234.00
- Revenue This Year
- NDMO N/A
- CRMD N/A
- Revenue Next Year
- NDMO N/A
- CRMD $246.41
- P/E Ratio
- NDMO N/A
- CRMD N/A
- Revenue Growth
- NDMO N/A
- CRMD 41184.20
- 52 Week Low
- NDMO $8.99
- CRMD $2.89
- 52 Week High
- NDMO $11.24
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- NDMO 58.54
- CRMD 70.88
- Support Level
- NDMO $10.08
- CRMD $7.91
- Resistance Level
- NDMO $10.25
- CRMD $13.09
- Average True Range (ATR)
- NDMO 0.11
- CRMD 0.70
- MACD
- NDMO 0.05
- CRMD 0.43
- Stochastic Oscillator
- NDMO 96.08
- CRMD 88.68
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.